- Paid samples of Sonanos™ are available, with GMP-compliant products planned for 2027.
- Sonanos™ PG and DS address sustained release and solubility challenges in drug formulation.
- Over 60 feasibility studies have been conducted with global pharmaceutical companies since 2020.
- Sonanos™ DV is in GMP production for cancer vaccine development.
Introduction of New Sonanos™ Grades
Asahi Kasei is set to launch two new specialty grades in its Sonanos™ portfolio, with paid samples already available. The products, manufactured in compliance with Good Manufacturing Practice (GMP), are scheduled for sale in 2027. Sonanos™ is designed to enhance injectable drug formulations, aligning with the company's strategy to grow in the pharmaceutical materials market.
Addressing Industry Challenges
The demand for biologics, peptides, and oncology therapies is rising, pressuring pharmaceutical companies to address formulation and delivery challenges. Sonanos™ offers sustained release and enhanced solubility, enabling long-acting injectables and expanding therapeutic possibilities.
Collaboration and Development
Since 2020, Asahi Kasei has partnered with global pharmaceutical companies for over 60 feasibility studies using Sonanos™ samples. This collaboration led to the development of Sonanos™ PG, optimized for sustained release, and Sonanos™ DS, designed to enhance solubility of poorly water-soluble APIs.
Future Plans and Applications
Samples of both grades with guaranteed analytical values are now available for nonclinical development. Asahi Kasei plans to supply GMP-compliant products in 2027, meeting international guidelines for pharmaceutical excipients. Additionally, Sonanos™ is advancing through DiveRadGel Inc., a spin-out venture applying the technology to cancer vaccine development, with Sonanos™ DV already in GMP production for early-stage clinical trials.
